Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)

ETCTN 10563: Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (clinicaltrials.gov)

P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026

5 days ago

Trial completion date • Trial primary completion date

pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • peposertib (M3814) • Duomeisu (pegylated liposomal doxorubicin)

10d

Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: a retrospective study. (PubMed, BMC Cancer)

Prior PLD therapy, impaired renal function, and pre-existing anemia substantially increased the risk of severe anemia during olaparib treatment. These findings highlight the need for risk-adaptive monitoring strategies and proactive management in patients with high risk for severe anemia. Further studies with larger cohorts of patients with renal impairment are recommended to support dose-adjustment strategies and optimize treatment safety.

10 days ago

Retrospective data • Journal

HRD (Homologous Recombination Deficiency)

HRD

Lynparza (olaparib) • pegylated liposomal doxorubicin

13d

PROTA: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (clinicaltrials.gov)

P1/2, N=29, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting

13 days ago

Enrollment closed • Platinum resistant

Keytruda (pembrolizumab) • pegylated liposomal doxorubicin • igrelimogene litadenorepvec (TILT-123)

14d

Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) (clinicaltrials.gov)

P2, N=54, Not yet recruiting, National Taiwan University Hospital

14 days ago

New P2 trial • Circulating tumor DNA

HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase)

HER-2 positive

Herceptin (trastuzumab) • Perjeta (pertuzumab) • cyclophosphamide • pegylated liposomal doxorubicin

17d

NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)

P2/3, N=444, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Apr 2027

17 days ago

Trial completion date • Platinum resistant

PD-L1 (Programmed death ligand 1)

Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)

18d

REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)

P2/3, N=860, Recruiting, Daiichi Sankyo | N=344 --> 860

18 days ago

Enrollment change • Platinum resistant

FOLR1 ( Folate receptor alpha )

FOLR1 expression

paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)

18d

TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)

P3, N=1100, Recruiting, AstraZeneca | N=309 --> 1100

18 days ago

Enrollment change • Trial initiation date • Platinum resistant

BRCA (Breast cancer early onset)

BRCA mutation

paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)

18d

MAESTRA 2: Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (clinicaltrials.gov)

P3, N=466, Recruiting, Incyte Corporation | N=286 --> 466

18 days ago

Enrollment change • Trial initiation date • Platinum resistant

FOLR1 ( Folate receptor alpha )

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan

19d

NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)

P3, N=579, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027

19 days ago

Trial completion date • Platinum sensitive

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)

BRCA2 mutation • BRCA1 mutation • BRCA mutation

Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)

22d

MAESTRA 2: Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (clinicaltrials.gov)

P3, N=286, Recruiting, Incyte Corporation

22 days ago

New P3 trial • Platinum resistant

FOLR1 ( Folate receptor alpha )

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan

24d

Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology. (PubMed, J Obstet Gynaecol Res)

PFI, histological subtype, PS, and CA125 levels are important prognostic factors for the use of molecular-targeted agents for recurrent epithelial ovarian cancer. Patients with CC and EM subtypes experience worse outcomes than those with HGS, highlighting the need for subtype-specific management in recurrent ovarian cancer.

24 days ago

Retrospective data • Journal • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)

BRCA2 mutation • BRCA1 mutation • HRD

Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin